| Accelerating Investment Matching for Biohealth Startups… Focused on Early-Stage Investments in Medical Devices, Pharmaceuticals, and Digital Health
Global pharmaceutical and biotech accelerator JNPMEDI Partners (CEO KwunHo Jeong) has been selected as a specialized institution for the 2025 Investment Attraction Support Program organized by the Korea Health Industry Development Institute (KHIDI).
This program aims to address the investment challenges faced by biohealth startups during their growth phase by strategically matching them with specialized investment institutions. Through this initiative, JNPMEDI Partners will provide customized support for startups in the medical device, pharmaceutical, and digital health sectors. This includes investment facilitation, commercialization consulting, networking opportunities, investor relations (IR) support, and regulatory consulting for global market entry, including FDA and EMA clinical approvals and technology transfer assistance.
JNPMEDI Partners is particularly focused on early-stage investments, connecting startups with funding ranging from KRW 10 million to KRW 1 billion across Angel, Seed, and Series A rounds. Recognized for its expertise in the biohealth industry and extensive clinical experience, JNPMEDI is well-positioned to bridge the gap between technological potential and market viability.
KHIDI has selected a total of six specialized institutions, each of which will be matched with five to six startups, with the goal of achieving substantial investment outcomes. JNPMEDI Partners aims to successfully secure investment for at least three of the companies it collaborates with under this program.
“This initiative goes beyond simple investment facilitation—it serves as a growth acceleration program, driving commercialization and global expansion,” said JaeHyun Lee, Director at JNPMEDI Partners. “We hope to support promising early-stage startups with meaningful technologies through this program.”
Applications for the Investment Attraction Support Program are currently open, and biohealth startups of all sizes are encouraged to apply. Through collaboration with JNPMEDI Partners, startups can explore opportunities for investment and business growth.
| Accelerating Investment Matching for Biohealth Startups… Focused on Early-Stage Investments in Medical Devices, Pharmaceuticals, and Digital Health
Global pharmaceutical and biotech accelerator JNPMEDI Partners (CEO KwunHo Jeong) has been selected as a specialized institution for the 2025 Investment Attraction Support Program organized by the Korea Health Industry Development Institute (KHIDI).
This program aims to address the investment challenges faced by biohealth startups during their growth phase by strategically matching them with specialized investment institutions. Through this initiative, JNPMEDI Partners will provide customized support for startups in the medical device, pharmaceutical, and digital health sectors. This includes investment facilitation, commercialization consulting, networking opportunities, investor relations (IR) support, and regulatory consulting for global market entry, including FDA and EMA clinical approvals and technology transfer assistance.
JNPMEDI Partners is particularly focused on early-stage investments, connecting startups with funding ranging from KRW 10 million to KRW 1 billion across Angel, Seed, and Series A rounds. Recognized for its expertise in the biohealth industry and extensive clinical experience, JNPMEDI is well-positioned to bridge the gap between technological potential and market viability.
KHIDI has selected a total of six specialized institutions, each of which will be matched with five to six startups, with the goal of achieving substantial investment outcomes. JNPMEDI Partners aims to successfully secure investment for at least three of the companies it collaborates with under this program.
“This initiative goes beyond simple investment facilitation—it serves as a growth acceleration program, driving commercialization and global expansion,” said JaeHyun Lee, Director at JNPMEDI Partners. “We hope to support promising early-stage startups with meaningful technologies through this program.”
Applications for the Investment Attraction Support Program are currently open, and biohealth startups of all sizes are encouraged to apply. Through collaboration with JNPMEDI Partners, startups can explore opportunities for investment and business growth.